The Moving Average Convergence Divergence (MACD) for CLDX turned positive on October 19, 2026. Looking at past instances where CLDX's MACD turned positive, the stock continued to rise in 37 of 46 cases over the following month. The odds of a continued upward trend are 80%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CLDX's RSI Indicator exited the oversold zone, 23 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on CLDX as a result. In 67 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
Following a +10.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLDX advanced for three days, in 205 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 50-day moving average for CLDX moved below the 200-day moving average on November 10, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
CLDX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CLDX entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. CLDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.283) is normal, around the industry mean (3.498). P/E Ratio (-6.867) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. CLDX's P/S Ratio (10000.000) is very high in comparison to the industry average of (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The RSI Indicator for STOK moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 24 of the 27 cases the stock moved higher. This puts the odds of a move higher at 89%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on STOK as a result. In 70 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for STOK just turned positive on October 15, 2026. Looking at past instances where STOK's MACD turned positive, the stock continued to rise in 38 of 47 cases over the following month. The odds of a continued upward trend are 81%.
STOK moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for STOK crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 78%.
Following a +6.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where STOK advanced for three days, in 269 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
STOK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 215 of 254 cases where STOK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STOK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.956) is normal, around the industry mean (3.498). P/E Ratio (-7.829) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (63.291) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 54 (best 1 - 100 worst), indicating steady price growth. STOK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 89 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STOK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
CLDX | STOK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 27 | 36 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 99 Overvalued | 29 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 89 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 58 | 54 | |
P/E GROWTH RATING 1..100 | 25 | 98 | |
SEASONALITY SCORE 1..100 | n/a | 23 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
STOK's Valuation (29) in the null industry is significantly better than the same rating for CLDX (99) in the Biotechnology industry. This means that STOK’s stock grew significantly faster than CLDX’s over the last 12 months.
STOK's Profit vs Risk Rating (89) in the null industry is in the same range as CLDX (100) in the Biotechnology industry. This means that STOK’s stock grew similarly to CLDX’s over the last 12 months.
STOK's SMR Rating (98) in the null industry is in the same range as CLDX (98) in the Biotechnology industry. This means that STOK’s stock grew similarly to CLDX’s over the last 12 months.
STOK's Price Growth Rating (54) in the null industry is in the same range as CLDX (58) in the Biotechnology industry. This means that STOK’s stock grew similarly to CLDX’s over the last 12 months.
CLDX's P/E Growth Rating (25) in the Biotechnology industry is significantly better than the same rating for STOK (98) in the null industry. This means that CLDX’s stock grew significantly faster than STOK’s over the last 12 months.
| CLDX | STOK | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 68% | 1 day ago 89% |
| Stochastic ODDS (%) | 1 day ago 74% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 79% | 1 day ago 85% |
| MACD ODDS (%) | 1 day ago 80% | 1 day ago 81% |
| TrendWeek ODDS (%) | 1 day ago 79% | 1 day ago 85% |
| TrendMonth ODDS (%) | 1 day ago 76% | 1 day ago 82% |
| Advances ODDS (%) | 3 days ago 77% | 3 days ago 88% |
| Declines ODDS (%) | 1 day ago 78% | 13 days ago 85% |
| BollingerBands ODDS (%) | 1 day ago 88% | 1 day ago 81% |
| Aroon ODDS (%) | 1 day ago 82% | 1 day ago 85% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CLDX’s FA Score shows that 1 FA rating(s) are green while STOK’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CLDX’s TA Score shows that 4 TA indicator(s) are bullish while STOK’s TA Score has 8 bullish TA indicator(s).
CLDX (@Biotechnology) experienced а +0.74% price change this week, while STOK (@Biotechnology) price change was +1.13% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
CLDX is expected to report earnings on Mar 01, 2027.
STOK is expected to report earnings on Mar 16, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with STOK. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then STOK could also see price increases.
| Ticker / NAME | Correlation To CLDX | 1D Price Change % | ||
|---|---|---|---|---|
| CLDX | 100% | -1.63% | ||
| STOK - CLDX | 48% Loosely correlated | +2.02% | ||
| MGTX - CLDX | 47% Loosely correlated | +0.62% | ||
| VYGR - CLDX | 46% Loosely correlated | -3.56% | ||
| LXEO - CLDX | 45% Loosely correlated | +0.33% | ||
| RXRX - CLDX | 45% Loosely correlated | +1.13% | ||
More | ||||
A.I.dvisor indicates that over the last year, STOK has been loosely correlated with RCKT. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if STOK jumps, then RCKT could also see price increases.
| Ticker / NAME | Correlation To STOK | 1D Price Change % | ||
|---|---|---|---|---|
| STOK | 100% | +2.02% | ||
| RCKT - STOK | 53% Loosely correlated | +1.22% | ||
| DYN - STOK | 53% Loosely correlated | +0.39% | ||
| TSHA - STOK | 51% Loosely correlated | +0.12% | ||
| SLDB - STOK | 50% Loosely correlated | +6.00% | ||
| QTTB - STOK | 49% Loosely correlated | -1.39% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| QUSA | 16.28 | 0.31 | +1.94% |
| Vistashares Target 15 Usa Quality Income ETF | |||
| XCOM | 24.15 | N/A | N/A |
| Corgi All Commodities 2x Daily ETF (XCOM) | |||
| LTPZ | 46.10 | -0.04 | -0.09% |
| PIMCO 15+ Year US TIPS Index Exchange-Traded Fund (LTPZ) | |||
| EIRL | 83.64 | -0.47 | -0.56% |
| iShares MSCI Ireland ETF (EIRL) | |||
| OIA | 5.74 | -0.06 | -1.03% |
| INVESCO Municipal Income OPPORTUNITIES TRUST | |||